EWA
RLAY icon

EverSource Wealth Advisors’s Relay Therapeutics RLAY Stock Holding History

EverSource Wealth Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.1K Buy
3,103
+227
+8% +$3.29K ﹤0.01% 1685
2026
Q1 		$28.6K Buy
2,876
+665
+30% +$5.95K ﹤0.01% 2267
2025
Q4 		$18.7K Hold
2,211
– – ﹤0.01% 2430
2025
Q3 		$11.5K Buy
2,211
+489
+28% +$1.86K ﹤0.01% 2738
2025
Q2 		$5.96K Buy
1,722
+1,627
+1,713% +$4.84K ﹤0.01% 3079
2025
Q1 		$249 Sell
95
-2,433
-96% -$9.53K ﹤0.01% 3649
2024
Q4 		$10.4K Sell
2,528
-3,222
-56% -$17.5K ﹤0.01% 1968
2024
Q3 		$40.7K Hold
5,750
– – ﹤0.01% 1150
2024
Q2 		$47.3K Buy
+5,750
New +$39.3K ﹤0.01% 1113

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

EverSource Wealth Advisors's RLAY Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Relay Therapeutics (RLAY) stake by 7.9% in Q2 2026, buying an estimated $3.29K and bringing the position to 3,103 shares worth $58.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

EverSource Wealth Advisors first reported a position in RLAY in Q2 2024 and has held it in 9 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • EverSource Wealth Advisors held 3,103 shares of Relay Therapeutics worth $58.1K as of Q2 2026.
  • EverSource Wealth Advisors bought 227 Relay Therapeutics shares in Q2 2026, an estimated $3.29K.
  • Relay Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1685 holding.
  • EverSource Wealth Advisors first reported a position in Relay Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.